



## The 10 Cheapest 100-Point *Wine Advocate* Wines

- We screened the 154 wines we have which score a clean **100 points from *Wine Advocate*** which are available on the global secondary market.
- The Top 10 **lowest priced 100-point WA wines** in the market today are (best value first) with prices in GBP:

| Position | Country   | Region          | Wine  | Year | Pack    | Score    | Price Per Point | Drinking Window | Price     |
|----------|-----------|-----------------|---|------|---------|----------|-----------------|-----------------|-----------|
| 1        | Spain     | Andalucia       | Toro Albala Don PX Convento Seleccion 1946 (6x75cl)                 | 1946 | 6x75cl  | 100 (WA) | £1.42           | 2060            | £850.00   |
| 2        | France    | Bordeaux        | Pontet-Canet 2010 (12x75cl)   | 2010 | 12x75cl | 100 (WA) | £1.44           | 2065            | £1,730.00 |
| 3        | France    | Rhone           | Chapoutier Ermitage De L'Oree Blanc 2013 (6x75cl)                   | 2013 | 6x75cl  | 100 (WA) | £1.52           | 2043            | £910.00   |
| 4        | France    | Bordeaux        | Cos d'Estournel 2016 (6x75cl)                                       | 2016 | 6x75cl  | 100 (WA) | £1.53           | 2068            | £920.00   |
| 5        | France    | Bordeaux        | Leoville Poyferre 2009 (12x75cl)                                    | 2009 | 12x75cl | 100 (WA) | £1.58           | 2040            | £1,900.00 |
| 6        | France    | Bordeaux        | Pape Clement 2010 (12x75cl)   | 2010 | 12x75cl | 100 (WA) | £1.61           | 2053            | £1,930.00 |
| 7        | Italy     | Tuscany         | Casanova di Neri Brunello di Montalcino Tenuta Nuova 2010 (1x150cl) | 2010 | 1x150cl | 100 (WA) | £1.66           | 2045            | £331.00   |
| 8        | Australia | South Australia | Clarendon Hills Astralis Shiraz 2010 (6x75cl)                       | 2010 | 6x75cl  | 100 (WA) | £1.71           | 2030            | £1,025.00 |
| 9        | France    | Bordeaux        | Pape Clement 2010 (6x75cl)  | 2010 | 6x75cl  | 100 (WA) | £1.72           | 2053            | £1,030.00 |
| 10       | France    | Bordeaux        | Leoville Poyferre 2009 (6x75cl)                                     | 2009 | 6x75cl  | 100 (WA) | £1.74           | 2040            | £1,045.00 |

Prices as at 6<sup>th</sup> March 2019. All available on [www.cruworldwine.com](http://www.cruworldwine.com)

- We believe that this basket of 10 wines will **outperform the boarder fine wine market** over the medium to long-term. This is because *Wine Advocate* (Robert Parker) 100-point wines retain a prestige which gives them a **global appeal** on which all collectors and investors can agree. It is like a bond having a AAA rating from S&P.
- The *average* price for a 100-point (75cl bottle) Bordeaux wine is **£5,500 per (6x75cl)**. This underlines how relatively undervalued the wines on this list are.
- It is interesting to see such a wide spread of countries and regions shown in the Top 10. **Bordeaux** has the largest share, with 6 wines, but there are also wines from **Italy, Spain** and **Australia**.
- All the wines on this list have plenty of room for further improvement in the bottle, ensuring that they have ample time to appreciate in value.
- **IMPORTANT NOTE:** *Many of the wines on the list have very low availability.*

**Dr Jeremy Howard**  
Head of Investment Research  
[jeremy.howard@cruworldwine.com](mailto:jeremy.howard@cruworldwine.com)

## IMPORTANT NOTICE

This report has been issued or approved for issue by an entity forming part of Cru (as defined below) and has been forwarded to you solely for your information and should not be considered as an offer or solicitation of an offer to sell, buy or subscribe to any securities or any derivative instrument or any other rights pertaining thereto ("financial instruments"). This report is intended for use by professional or business investors only. This report may not be reproduced without the consent of Cru.

The information and opinions expressed in this report have been compiled from sources believed to be reliable, but, neither Cru, nor any of its directors, officers, or employees accepts liability from any loss arising from the use hereof or makes any representations as to its accuracy and completeness. Any opinions, forecasts or estimates herein constitute a judgement as at the date of this report. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance. This information is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the product or products mentioned. Cru is not agreeing to nor is it required to update the opinions, forecasts or estimates contained herein.

The value of any products mentioned in this report can fall as well as rise. Foreign currency denominated products are subject to fluctuations in exchange rates that may have a positive or adverse effect on the value, price or income of such products.

This report does not have regard to the specific instrument objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any products or investment strategies discussed in this report.

Cru (or its directors, officers or employees) may, to the extent permitted by law, own or have a position in the products of any company or related company or products referred to herein, and may add to or dispose of any such position or may make a market or act as a principal in any transaction in such products. Directors of Cru may also be directors of any of the companies mentioned in this report. Cru (or its directors, officers or employees) may, to the extent permitted by law, act upon or use the information or opinions presented herein, or research or analysis on which they are based prior to the material being published. Cru may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them.

For the purposes of this disclaimer, "Cru" shall mean: (i) Cru London Limited; (ii) Cru Asia Limited and (iii) from time to time, in relation to Cru London Limited and/or Cru Asia Limited, the ultimate holding company of that entity, a subsidiary (or a subsidiary of a subsidiary) of that entity, a holding company of that entity or any other subsidiary of that holding company, and any affiliated entity of any such entities.

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of an entity within Cru. Products referred to in this research report may not be eligible for sale in those jurisdictions where an entity within Cru is not authorised or permitted by local law to do so. In particular, Cru does not allow the redistribution of this report to non-professional investors or persons outside the jurisdictions referred to above and Cru cannot be held responsible in any way for third parties who effect such redistribution or recipients thereof. © 2019.